1. Department of Health and Aged Care. Notice of final decisions to amend (or not amend) the current Poisons Standard in relation to psilocybine and MDMA. Feb 2023. https://www.tga.gov.au/sites/default/files/2023-02/notice-of-final-decision-to-amend-or-not-amend-the-current-poisons-standard-june-2022-acms-38-psilocybine-and-mdma.pdf (p 8)
2. Government of Canada. Psilocybin and psilocin (Magic mushrooms): Health Canada’s special access program. Updated 8 Feb 2023. https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/magic-mushrooms.html#a22
3. Multidisciplinary Association for Psychedelic Studies. Israel approves compassionate use of MDMA-assisted therapy for PTSD. 4 Feb 2019. https://maps.org/2019/02/04/israel-approves-compassionate-use-of-mdma-assisted-psychotherapy-for-ptsd/
4. Multidisciplinary Association for Psychedelic Studies. FDA agrees to expanded access program for MDMA-assisted therapy for PTSD. 17 Jan 2020. https://maps.org/news/media/press-release-fda-agrees-to-expanded-access-program-for-mdma-assisted-psychotherapy-for-ptsd/
5. House of Commons Library (UK). Debate on access to psilocybin treatments. 18 May 2023. https://commonslibrary.parliament.uk/research-briefings/cdp-2023-0108/